# Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis

> **NCT00456092** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 204 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Apremilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00456092
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03-05
- **Primary completion:** 2009-05-09
- **Final completion:** 2009-05-09
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2020-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00456092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00456092, "Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00456092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*